Posts for Ticker ‘JAZZ’

Top Day Trader Alerts (JASO, GRMN, YRCW, JAZZ, MEDX, BMY, PETD, TOL, XHB, BRCM)

These are this morning’s top day trader alerts and most active in price and volume.  We have more detailed analysis and data on price and volume with links through to each at VSInvestor.com:

JA Solar Holding Co. (NASDAQ: JASO) is down close to 10% after poor results.

Garmin Ltd. (NASDAQ: GRMN) is down over 5% on a key analyst downgrade.

YRC Worldwide, Inc. (NASDAQ: YRCW) was down over 7% on an analyst downgrade.

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) was up almost 20% on an unexpected profit.

Medarex Inc. (NASDAQ: MEDX) is seeing very unusual merger arb volume after the Hart-Scott-Rodino merger review period for the Bristol-Myers Squibb (NYSE: BMY) buyout has expired.

Petroleum Development Corporation (NASDAQ: PETD) is down 5% and will be an exponential volume mover on the secondary offering.

Toll Brothers (NYSE: TOL) has some sales gains data that is strong enough to lift the SPDR S&P Homebuilders (NYSE: XHB).

This was not seen until a post-close review, but Broadcom Corp. (NASDAQ:BRCM) was seeing some very unusual PUT OPTIONS TRADING yesterday.

JON C. OGG
AUGUST 12, 2009

Posted on: August 12, 2009 – 9:26 am in Pre-Market Activity, Trading Alert, , , , , , , , , ,

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:

Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care companies are rising despite making health care reform concessions, as shareholders see they have a seat at the bargaining table.

Mylan Inc. (NASDAQ: MYL) has received FDA approval for a generic version of an AstraZeneca (AZN) prostate cancer drug — a rather unusual new generic.

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 25 percent after the company took steps to ease a cash crunch that had curtailed drug development.

King Pharmaceuticals (KG) and Pain Therapeutics (PTIE) said  they expect to resubmit a new drug application in mid-2010, slightly later than anticipated.

GlaxoSmithKline (NYSE: GSK) announced a positive study on its Cervarix vaccine, although it’s unclear if the company can play catch-up to Merck & Co.’s (NYSE: MRK) Gardasil.

See our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 7, 2009 – 11:03 am in Biotech, Drug companies, FDA, Medical, Trading Alert, , , , , , , , , , ,

Top Analyst Upgrades and Downgrades (CETV, CQB, CME, CFX, JAZZ, OSG, PII, UBS, WBS)

These are the top early-bird analyst calls with upgrades and downgrades seen this Friday morning with over two hours until the market opens:

  • Central European Media (CETV) Raised to Neutral at JPMorgan.
  • Chiquita Brands (CQB) Raised to Buy at Janney Montgomery Scott.
  • CME (CME) Raised to Neutral at JPMorgan.
  • Colfax (CFX) Raised to Buy ar KeyBanc.
  • Jazz Pharmaceuticals (JAZZ) Cut to Underweight at Barclays.
  • Overseas Shipholding Group (OSG) Cut to Market Perform at FBR.
  • Polaris (PII) Raised to Outperform at RBC.
  • UBS (UBS) Raised to Outperform at Credit Suisse.
  • Webster Financial (WBS) Raised to Market Perform at FBR.

Jon C. Ogg
June 26, 2009

Posted on: June 26, 2009 – 6:21 am in Analyst Calls, , , , , , , , ,